Summary & Overview
HCPCS Level II J0586: Injection, AbobotulinumtoxinA, 5 Units
HCPCS Level II code J0586 denotes an injectable dose of abobotulinumtoxinA measured as 5 units per billing increment. This code captures administration of a widely used botulinum toxin formulation for neuromuscular spasticity, focal dystonias, and select aesthetic indications. Nationally, accurate use of J0586 matters for consistent clinical documentation, inventory tracking, and payer adjudication across outpatient and office-based procedures.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of clinical context and billing intent, an overview of payer coverage considerations, common modifier usage (listed separately), and benchmarking insights where available. The publication outlines reimbursement benchmarks, billing pitfalls, and recent policy updates affecting administration of abobotulinumtoxinA.
This summary serves clinicians, practice managers, and revenue cycle professionals seeking a national-level reference on coding and billing for abobotulinumtoxinA injections. Data not available in the input is noted where applicable; the content focuses on code definition, service setting, and what readers can expect to learn about coverage and billing practices.
Billing Code Overview
HCPCS Level II code J0586 represents an injectable formulation of abobotulinumtoxinA supplied in an increment of 5 units per billing unit. The service type is therapeutic injection, commonly used for neuromuscular conditions and certain cosmetic indications where intramuscular injection of abobotulinumtoxinA is indicated.
The typical site of service for this code is outpatient clinic or physician office, including specialty neurology, physiatry, dermatology, and plastic surgery settings where injectable neurotoxins are administered under clinical supervision.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to a neurology or physical medicine and rehabilitation clinic with focal muscle spasticity or cervical dystonia that has not adequately responded to oral therapies and physical therapy. After evaluation, the clinician documents focal muscle groups contributing to functional impairment or pain. The clinician and patient discuss off-label and on-label uses of botulinum toxin. The patient receives an intramuscular injection of J0586 (abobotulinumtoxinA) using sterile technique, often guided by palpation, electromyography (EMG), or ultrasound when precise localization is needed. The service is usually delivered in an outpatient clinic, ambulatory surgical center, or physician office. Observation for immediate adverse effects occurs for a short period post-injection. Billing reflects units of J0586 administered; documentation includes injection sites, total units, lot numbers, informed consent, baseline and expected functional outcomes, and any guidance modality used (EMG/ultrasound).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Office or other outpatient visit for evaluation and management provided on the same day as another service | When E/M is documented and billed the same day as the injection and meets separate E/M requirements |